CA
JAZZ icon

Continuum Advisory’s Jazz Pharmaceuticals JAZZ Stock Holding History

Continuum Advisory’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-55
Closed -$6.83K – 1024
2025
Q1 		$6.83K Sell
55
-3
-5% -$391 ﹤0.01% 1060
2024
Q4 		$7.14K Sell
58
-3
-5% -$354 ﹤0.01% 1065
2024
Q3 		$7.58K Hold
61
– – ﹤0.01% 1066
2024
Q2 		$6.51K Hold
61
– – ﹤0.01% 1036
2024
Q1 		$6.9K Buy
+61
New +$7.47K ﹤0.01% 1021

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Continuum Advisory's JAZZ Position: Q2 2025 in Review

Continuum Advisory sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 55 shares — an estimated $6.83K sold.

Continuum Advisory first reported a position in JAZZ in Q1 2024 and held it in 5 quarters. The position peaked at $7.58K in Q3 2024. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

  • Continuum Advisory reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 55 Jazz Pharmaceuticals shares in Q2 2025, an estimated $6.83K.
  • Continuum Advisory first reported a position in Jazz Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Continuum Advisory's Jazz Pharmaceuticals position peaked at $7.58K in Q3 2024.
  • 501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.